Emmaus Life Sciences Obtains $1,700,000 New Round

  • Feed Type
  • Date
    1/27/2016
  • Company Name
    Emmaus Life Sciences
  • Mailing Address
    21250 Hawthorne Blvd. Torrance, CA 90503 USA
  • Company Description
    The mission of Emmaus Life Sciences is to improve the lives of people with rare disease by the discovery, development and commercialization of innovative treatments and therapies for rare and orphan diseases.
  • Website
    http://www.emmausmedical.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $1,700,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    The funds will be used to advance Emmaus’ pharmaceutical grade L-glutamine treatment (PGLG), which is currently under clinical development having completed its Phase 3 trial for the management of sickle cell disease (SCD), and for general corporate purposes.
  • M&A Terms
  • Venture Investor
    Korea Bio Medical Science Institute